
|Articles|December 2, 2014
CAR T Cell Therapies for ALL and NHL
Author(s)Marcel R.M. van den Brink, MD, PhD
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
Advertisement
Clinical Pearls
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
- A phase I study will be presented at ASH evaluating CAR T cell therapy directed against CD19 for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
- Another phase I study evaluated high dose therapy and ASCT followed by CAR T cell therapy directed against CD19 for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















